THIS SHARE WILL BE WORTH 3.00 IN 2009

Looking at the share price over the last couple of weeks, it is obvious that the news released today had obviously leaked.
The thing is how much has this been priced into the sp.
Not good. But with bio/drug companies knocks such as these are to be expected.
I see a 10% drop before the sp picks up again.

Protherics said it has agreed to provide additional manufacturing and stability data requirements to support a Biologicals License Application for its Voraxaze in the US, following its recent successful talks with the FDA. The FDA has also agreed to Protherics resubmitting its application as a rolling submission, starting in early 2008.

Protherics will continue to supply Voraxaze on a named patient basis in Europe for intervention use in patients at risk of severe or life-threatening methotrexate (anti-cancer agent) toxicity, the biopharmaceutical company said.

Separately, the company said it presented 'encouraging' OncoGel phase 2a oesophageal cancer data at a US conference and that it is planning to undertake a phase 2b study of the product in combination with chemoradiotherapy in patients in the second half of 2007.

Always good to see an institution increase their holdings a few days prior to results.
They could also be taking advantage of the sp reduction over the last couple of weeks. Still if they thought the sp would drop after tomorrow, they would had held off buying till then. Let's hope they got it right.

Results.

Revenues up 31.1 mill from 17.7 mill.
Profits (gross) 19.8 mill from 6.4 mill

Research/development, big increase.
Year loss less than market expectations at 3.6 mill down from 9.6 mill

Cash up to 40 mill from 9.6 mill.

Progress looking good in all areas, apart from the recent hiccup we all know about.

All in all a good year for Protherics, with future prospects looking excellent.

Although early I would have expected more trades and a rise in the SP by now.
No doubt many are looking at the cash increase as being mainly from the fund raising, instead of the bottom line.
Protherics are cash strong with the present cash burn not putting the company at risk.
It looks as if many were expecting the results to be better re more jam today (now) but drug, bio type companies don't work like this.
Still expect the institutions to increase their holdings.

I dont see any reason for SP improvement this year.
This explains the move out of PTI recently.

Put your cash elswhere till early next year!

well it goes from bad to worse!!!

Agreed - appalling day!

Still strongly believe in this share, but obviously can only concur.

Ouch!

Im very tempted to get out now while there is something left.
This is all too familiar!

Nice to see a director, buying. 50,000 @ 58.5p cant be bad.
The price when bought was parallel to the sp buy at that time.

25k is nothing to those guys.
its a sham to bolster some confidence after recent falls.

Transco,

25k is a fair amount of money, (OK obviously to some people it is just a bit of pocket money) but no one is willing to throw this amount at a lost cause.

Gary Watts is a businessman of some considerable experience. I don't think he would invest this amount if he did not believe he was going to get a good return on the investment.

Garry Watts is currently the Chief Executive Officer of SSL International PLC having previously held the position of Finance Director and Managing Director for Europe. He is also a Non-executive Director of the Medicines and Healthcare Products Regulatory Agency (MHRA), where he chairs the Audit and Risk Committee. Previously, he held executive directorships at Celltech Group plc and Medeva plc. He is a Chartered Accountant and was previously a partner with KPMG, leading the UK healthcare and life science practice.

Nice write up in iii by Edmond Jackson. Dated 29.07.07.

Protherics has potential to double.

It's tricky to discern value in a loss-making business with major potential and its shares currently out of favor. In the case of Protherics (PTI), this is no flaky operation launched on the latest fashion: the company is at the cutting edge of critical care and cancer products, with genuinely valuable relationships with major pharmaceutical groups such as AstraZeneca (AZN).

It goes on to talk about frustration of shareholders festering, and also mentions that sentiment is affected due to pre-tax loss will widen from 3.6 million to 17.5 million in its current financial year to end-March 2008.
It also mentions Protherics huge potential and that although a speculative share, its business plan and good steady cash flow.

All in all a good well balanced report.

Due to copywrite, extracts only.

thanks for that greek

Nice update re Prolarix(TM) phase 1 liver cancer study.

Phase 2 liver cancer study to start in early 2008 by Protherics, with Cancer Research UK reporting on phase 1 also early 2008.

As we know these trials take time and can't be rushed. The important thing is that activation was indicated in ALL patients in the phase 1 trial group.

Progressing nicely.

Interim management statement reads very positive.
The future looks good.

Looks like AXA have increased their holdings a tad (31,702 ). Every little helps

Just goes to show how the market in general can drag companies down.

On Thursday Protherics was among the biggest percentage gainers in Thursday's trading among companies with market capitalizations under $500 million. (no doubt due to the AGM and statement). Even allowing for the UK/USA drop.

Then with nothing directly involving Protherics, this occurs.

On Friday Protherics was among the biggest percentage losers in Thursday's trading among companies with market capitalizations under $500 million.